Hypertension Clinical Trial
— HUSHOfficial title:
Pragmatic Trial of Behavioral Interventions for Insomnia in Hypertensive Patients
Verified date | September 2020 |
Source | University of Pittsburgh |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Insomnia and hypertension are common health problems that often occur together and influence each other. This practical, low-cost, clinical trial will evaluate two behavioral treatments for insomnia (a brief intervention with therapist contact and a self-guided Internet intervention) compared to usual care. Participants will be recruited using the electronic health record in their primary care physicians' offices, and will be evaluated for sleep, blood pressure, and health outcomes after 9 weeks, 6 months, and 12 months.
Status | Completed |
Enrollment | 542 |
Est. completion date | March 5, 2020 |
Est. primary completion date | March 5, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 100 Years |
Eligibility |
Inclusion Criteria: 1. Hypertension diagnosis 'Hypertension diagnosis' is indicated by the presence of at least one of the following: 1. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis of essential hypertension in the electronic health record; 2. Hypertension listed in the medical problem list in the electronic health record. 2. At least one of the following: 1. Hypnotic on active med list 2. Insomnia on diagnosis or problem list 3. Age 18 years and up. 4. Meets criteria for DSM-5 (Diagnostic and Statistical Manual of Mental Disorders-5th ed.) Insomnia Disorder 5. At least moderate insomnia severity: Score > 7 on Insomnia Severity Index 6. Telephone, e-mail address, reliable Internet access. 'Reliable internet access' is defined by an individual having a personal e-mail address and having regular internet access within his/her own residence. 7. Stable medical, psychiatric condition Exclusion Criteria: 1. Untreated current major depression (Patient Health Questionnaire (PHQ-9) score equal to or greater than 15; Generalized Anxiety Disorder (GAD-7) score > 10); patients using stable (3 mos) medication, psychological treatment ARE eligible 2. History of bipolar disorder or psychosis 3. Substance use disorder within past 3 months 4. Dementia or probable dementia diagnosis 5. Active suicidal ideation or psychosis 6. Delayed sleep phase disorder (DSPD) or severe, untreated restless legs syndrome (RLS) 7. Plans to leave present source of care during the following year 8. Non-English speaking, illiterate, or sensory deficits 9. Shift work that includes working the night shift (between the hours of 12:00 a.m. - 6:00 a.m.) 10. Apnea Hypopnea Index (AHI) greater than or equal to 50 or O2 saturation 85% or less for > or = to 10% of the night. |
Country | Name | City | State |
---|---|---|---|
United States | UPMC Health System | Pittsburgh | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
University of Pittsburgh | Carolinas Medical Center, National Heart, Lung, and Blood Institute (NHLBI), University of Virginia |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Daytime Impairment Related to Sleep | PROMIS Sleep Related Impairment is a self-report measure that assesses problems related to insufficient sleep during the past 7 days. It is administered by computerized adaptive testing (CAT) with individual responses guiding the system's choice of subsequent items from the full 16-item bank. Scale Range: Item responses are combined to yield a T-score with population mean of 50, standard deviation of 10, and range of ~20 - ~80. Higher scores indicate greater sleep related impairment. |
9 weeks, 6 months, 12 months | |
Other | Side Effects | Side effects (frequency, severity, impairment) are recorded via a self-report that was adapted from the Fisber. Range: 22 Minimum Score: 0 (no side effects; better) Maximum Score: 21 (worse) Those reporting severity of > moderate and/or frequency > 50% of the time in their self-report, or who spontaneously report a side effect, are contacted by the study coordinator. Information is gathered regarding the nature and duration of the event and action taken. Determination of causality and outcomes attributed to the event are then made. |
9 weeks, 6 months, 12 months | |
Other | Insomnia Severity | The Insomnia Severity Index (ISI) is a 7-item self-report questionnaire that measures severity of insomnia symptoms during the last two weeks. Scale Range: Minimum Score = 0 (no insomnia); Maximum Score = 28 (severe insomnia) |
9 weeks, 6 months, 12 months | |
Other | Sleep Quality | The Pittsburgh Sleep Quality Index (PSQI) is an 18-item self-report measure that assesses sleep quality in the past month. These items are combined into seven component scores (subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbance, use of sleep medication, and daytime dysfunction). The seven component scores are added to produce a global sleep quality score. Higher global scores reflect lower sleep quality, with 5 as a cut-off distinguishing good from poor sleepers. Scale Range: 22 Minimum Score = 0 (better); Maximum Score = 21 (worse) |
9 weeks, 6 months, 12 months | |
Other | Daytime Sleepiness | The Epworth Sleepiness Scale (ESS) is an 8-item self-report measure that assesses daytime sleepiness by asking about the likelihood of dozing in certain situations. Individual items are summed to yield the ESS score. Scale Range: 25 Minimum Score = 0 (never doze); Maximum Score = 24 (doze a lot) |
9 weeks, 6 months, 12 months | |
Other | Falls | Falls are recorded via self-report. Range: 5 Minimum Score: 0 (no falls; better) Maximum Score: 5 (> 4 falls; worse) Those reporting a fall are contacted by the coordinator and information is gathered regarding the date and time of day of the fall(s), proximity to a sleep episode, contributing factors, and whether or not medication for sleep or anxiety were taken in the 24 hours preceding the fall. |
9 weeks, 6 months, 12 months | |
Other | Improvement | The Patient Global Impression of Improvement (PGI-I) Scale is a self-report measure that rates perceived response to intervention. Scale Range: 7 Minimum Score: 1 (very much improved; better) Maximum Score: 7 (very much worse; worse) |
9 weeks, 6 months, 12 months | |
Other | Bed times | The in and out of bed times are recorded in a 7-day sleep diary and include: bed time, lights out time, wake time, and out-of-bed time. Bed time is the clock time when the participant got into bed. Lights out time is the clock time when the participant actually attempted to sleep (i.e., turned out the lights). Wake time is the clock time of the participant's final awakening. Out-of-bed time is the clock time they got out of bed for the day. Ranges for these clock-time variables use 24 hours, with no minimum or maximum value. |
Intervention, 9 weeks, 6 months, 12 months | |
Other | Time to fall asleep | Time to fall asleep is recorded in a 7-day sleep diary. Range: 24 hours Minimum value = 0 minutes (better) Maximum value = 1440 minutes (worse) |
Intervention, 9 weeks, 6 months, 12 months | |
Other | Wake After Sleep Onset (WASO) | WASO is recorded in a 7-day sleep diary, and refers to the number of minutes of wakefulness between the time of falling asleep and Wake Time. Range: 24 hours Minimum value = 0 minutes (better) Maximum value = 1440 minutes (worse) |
Intervention, 9 weeks, 6 months, 12 months | |
Other | Subjective Sleep Quality | Subjective sleep quality is recorded in a 7-day sleep diary. Range: 5 Minimum score: 0 (very poor; worse) Maximum score: 4 (very good; better) |
Intervention, 9 weeks, 6 months, 12 months | |
Other | Use of Sleep Medication | Use of sleep medication is recorded in a 7-day sleep diary, with the ability to report up to 3 medications taken on a given night. Scale Range: 22 Minimum Score: 0 (no sleep medication use on any night; better) Maximum Score: 21 (multiple sleep medications and/or multiple nights of use; worse). |
Intervention, 9 weeks, 6 months, 12 months | |
Other | Sleep Efficiency | Sleep Efficiency is calculated from values recorded in a 7-day sleep diary. It refers to the percentage of time asleep while in bed. Time in bed is calculated as (Out of bed time) - (Bed time), in minutes. Sleep efficiency is calculated as (Total sleep time/time in bed) X 100. Range: 101 Minimum for sleep efficiency: 0% (worse) Maximum for sleep efficiency: 100% (better) |
Intervention, 9 weeks, 6 months, 12 months | |
Primary | Sleep Disturbance | Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance: PROMIS Sleep Disturbance measures self-reported sleep quality and associated daytime functioning during the past seven days. It is administered by computerized adaptive testing (CAT) with individual responses guiding the system's choice of subsequent items from the full 27-item item bank. Scale Range: Item responses are combined to yield a T-score with population mean of 50, standard deviation of 10, and range of ~20 - ~80. Higher scores indicate greater Sleep Disturbance. |
9 weeks | |
Secondary | Depression | The PROMIS Depression Scale is a self-report measure that assesses negative mood, views of self, social cognition, affect and engagement during the past seven days. It is administered by computerized adaptive testing (CAT) with individual responses guiding the system's choice of subsequent items from the full 28-item bank. Scale Range: Item responses are combined to yield a T-score with population mean of 50, standard deviation of 10, and range of ~20 - ~80. Higher scores indicate greater Depression. |
9 weeks, 6 months, 12 months | |
Secondary | Anxiety | The PROMIS Anxiety Scale is a self-report measure that assesses fear, anxiousness, and hyperarousal and its associated somatic symptoms during the past seven days. It is administered by computerized adaptive testing (CAT) with individual responses guiding the system's choice of subsequent items from the full 29-item bank. Scale Range: Item responses are combined to yield a T-score with population mean of 50, standard deviation of 10, and range of ~20 - ~80. Higher scores indicate greater Anxiety. |
9 weeks, 6 months, 12 months | |
Secondary | Fatigue | The PROMIS Fatigue Scale is a self-report measure that assesses the experience and impact of fatigue during the past seven days. It is administered by computerized adaptive testing (CAT) with individual responses guiding the system's choice of subsequent items from the full 95-item bank. Scale Range: Item responses are combined to yield a T-score with population mean of 50, standard deviation of 10, and range of ~20 - ~80. Higher scores indicate greater Fatigue. |
9 weeks, 6 months, 12 months | |
Secondary | Blood Pressure | Home blood pressures are measured with an Omron BP786 home blood pressure monitor. Reported values for each day in each participant represent the average systolic and diastolic readings and heart rate from 3 measurements. Participants record these values in a 7-day sleep diary. Daily measurements for each participant are averaged across the number of days of recording. Scale Range: Systolic BP range: 0 - 299; Diastolic BP range: 0 - 299; Heart rate range: 40 - 180. These values represent the reliable ranges for the device. For each variable, higher values are generally considered "worse" and lower values "better." However, very low values (e.g., systolic BP values <80, diastolic BP values <60, and HR values <50) may also indicate poor cardiovascular health. |
9 weeks, 6 months, 12 months | |
Secondary | Hypnotic Use | Daily hypnotic use is self-reported in a 7-day sleep diary, with the ability to report up to 3 medications taken on a given night. Scale Range: 22 Minimum Score: 0 (no hypnotic medication use on any day; better) Maximum Score: 21 (multiple hypnotic medications and/or multiple days of use; worse). Retrospective hypnotic use in past 3 months is self-reported in a demographic and health care utilization questionnaire. Scale Range: 0 - no limit Minimum Score: 0 (better) Maximum Score: no limit (multiple hypnotic medications and/or multiple days of use; worse). |
9 weeks, 6 months, 12 months | |
Secondary | Health Care Utilization | The Health care utilization Questionnaire is a self-report measure that asks about recent health care services that have been sought and medications for hypertension and insomnia. Scale Range: 0 - no limit Minimum Score: 0 (no visits or medications; better) Maximum Score: no limit (multiple visits and/or medications; worse) |
9 weeks, 6 months, 12 months | |
Secondary | Health-Related Quality of Life | The Rand-12 is a 12-item self-report measure that produces physical health (PHC) and mental health (MHC) component scores. T-scores are used and have a population mean of 50. Scale Range (PHC and MHC): 100 Minimum Score (PHC and MHC) = 0 (worse) Maximum Score (PHC and MHC) = 100 (better) |
9 weeks, 6 months, 12 months | |
Secondary | Client Satisfaction | The Client Satisfaction Questionnaire (CSQ) is an 8-item self-report measure that assesses client satisfaction with the services they received. Scale Range: 24 Minimum Score = 8 (low satisfaction) Maximum Score = 32 (high satisfaction) |
9 weeks | |
Secondary | Provider Satisfaction | The provider satisfaction questionnaire is a self-report measure that assesses provider's perceived efficacy of the treatments their patients received, barriers to treatment, and satisfaction of both providers and patients. Scale Range: 38 Minimum Score: 0 (low satisfaction) Maximum Score: 37 (high satisfaction) |
Following closing of recruitment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04591808 -
Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia
|
Phase 3 | |
Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
Completed |
NCT05433233 -
Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension
|
N/A | |
Completed |
NCT05491642 -
A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses
|
Phase 1 | |
Completed |
NCT03093532 -
A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT05529147 -
The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly
|
||
Recruiting |
NCT06363097 -
Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
|
||
Recruiting |
NCT05976230 -
Special Drug Use Surveillance of Entresto Tablets (Hypertension)
|
||
Completed |
NCT06008015 -
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT05387174 -
Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period
|
N/A | |
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Recruiting |
NCT05121337 -
Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension
|
N/A | |
Withdrawn |
NCT04922424 -
Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men
|
Phase 1 | |
Active, not recruiting |
NCT05062161 -
Sleep Duration and Blood Pressure During Sleep
|
N/A | |
Completed |
NCT05087290 -
LOnger-term Effects of COVID-19 INfection on Blood Vessels And Blood pRessure (LOCHINVAR)
|
||
Not yet recruiting |
NCT05038774 -
Educational Intervention for Hypertension Management
|
N/A | |
Completed |
NCT05621694 -
Exploring Oxytocin Response to Meditative Movement
|
N/A | |
Completed |
NCT05688917 -
Green Coffee Effect on Metabolic Syndrome
|
N/A | |
Recruiting |
NCT05575453 -
OPTIMA-BP: Empowering PaTients in MAnaging Blood Pressure
|
N/A |